# Cineverse Corp.: financial statements, quarterly

CNVS · Nasdaq · CIK 1173204 · [Communication](/sectors/communication.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/cnvs.md) · [Financials](/companies/cnvs/financials.md) · [Filings](/companies/cnvs/filings.md) · [Insiders](/companies/cnvs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnvs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.0](/filings/0000950170-24-127165.md) | [13.3](/filings/0000950170-25-021401.md) | [9.9 d](/filings/0000950170-25-091741.md) | [9.1](/filings/0000950170-25-109033.md) | [12.7](/filings/0001193125-25-283349.md) | [40.7](/filings/0001193125-26-055008.md) | [15.6 d](/filings/0001193125-26-284027.md) | [11.1](/filings/0001193125-26-349428.md) | [12.4](/filings/0001193125-25-283349.md) | [16.3](/filings/0001193125-26-055008.md) | [26.0 d](/filings/0001193125-26-284027.md) | [30.6](/filings/0001193125-26-349428.md) |
| Selling, general and administrative | $m | [6.8](/filings/0000950170-24-127165.md) | [6.4](/filings/0000950170-25-021401.md) | [6.8 d](/filings/0000950170-25-091741.md) | [6.6](/filings/0000950170-25-109033.md) | [6.4](/filings/0001193125-25-283349.md) | [9.4](/filings/0001193125-26-055008.md) | [5.4 d](/filings/0001193125-26-284027.md) | [9.0](/filings/0001193125-26-349428.md) | [11.4](/filings/0001193125-25-283349.md) | [10.7](/filings/0001193125-26-055008.md) | [12.3 d](/filings/0001193125-26-284027.md) | [11.6](/filings/0001193125-26-349428.md) |
| Operating income | $m | [0.6](/filings/0000950170-24-127165.md) | [0.4](/filings/0000950170-25-021401.md) | [(14.0) d](/filings/0000950170-25-091741.md) | [(2.8)](/filings/0000950170-25-109033.md) | [(0.9)](/filings/0001193125-25-283349.md) | [9.4](/filings/0001193125-26-055008.md) | [2.1 d](/filings/0001193125-26-284027.md) | [(3.7)](/filings/0001193125-26-349428.md) | [(5.4)](/filings/0001193125-25-283349.md) | [(0.7)](/filings/0001193125-26-055008.md) | [(5.4) d](/filings/0001193125-26-284027.md) | [(5.1)](/filings/0001193125-26-349428.md) |
| Interest expense | $m | [0.2](/filings/0000950170-24-127165.md) | [0.3](/filings/0000950170-25-021401.md) | [0.3 d](/filings/0000950170-25-091741.md) | [0.4](/filings/0000950170-24-097132.md) | [0.3](/filings/0000950170-24-127165.md) | [2.3](/filings/0000950170-25-021401.md) | [1.3 d](/filings/0000950170-25-091741.md) | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-127165.md) | [(0.0)](/filings/0000950170-25-021401.md) | [(0.0) d](/filings/0000950170-25-091741.md) | [0.0](/filings/0000950170-25-109033.md) | [0.0](/filings/0001193125-25-283349.md) | [0.0](/filings/0001193125-26-055008.md) | [0.1 d](/filings/0001193125-26-284027.md) | [0.0](/filings/0001193125-26-349428.md) | [0.0](/filings/0001193125-25-283349.md) | [0.0](/filings/0001193125-26-055008.md) | [(2.9) d](/filings/0001193125-26-284027.md) | [0.0](/filings/0001193125-26-349428.md) |
| Net income | $m | [(0.3)](/filings/0000950170-25-021401.md) | [(2.7)](/filings/0000950170-25-021401.md) | [(14.7) d](/filings/0000950170-25-091741.md) | [(3.1)](/filings/0001193125-26-055008.md) | [(1.2)](/filings/0001193125-26-055008.md) | [7.2](/filings/0001193125-26-055008.md) | [0.9 d](/filings/0001193125-26-284027.md) | [(3.5)](/filings/0001193125-26-349428.md) | [(5.5)](/filings/0001193125-26-055008.md) | [(0.9)](/filings/0001193125-26-055008.md) | [1.3 d](/filings/0001193125-26-284027.md) | [(5.7)](/filings/0001193125-26-349428.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-127165.md) | [(0.22)](/filings/0000950170-25-021401.md) | not reported | [(0.20)](/filings/0000950170-25-109033.md) | [(0.09)](/filings/0001193125-25-283349.md) | [0.34](/filings/0001193125-26-055008.md) | not reported | [(0.21)](/filings/0001193125-26-349428.md) | [(0.31)](/filings/0001193125-25-283349.md) | [(0.05)](/filings/0001193125-26-055008.md) | not reported | [(0.28)](/filings/0001193125-26-349428.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-127165.md) | [(0.22)](/filings/0000950170-25-021401.md) | not reported | [(0.20)](/filings/0000950170-25-109033.md) | [(0.09)](/filings/0001193125-25-283349.md) | [0.38](/filings/0001193125-26-055008.md) | not reported | [(0.21)](/filings/0001193125-26-349428.md) | [(0.31)](/filings/0001193125-25-283349.md) | [(0.05)](/filings/0001193125-26-055008.md) | not reported | [(0.28)](/filings/0001193125-26-349428.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.6](/filings/0000950170-23-063839.md) | [5.5](/filings/0000950170-24-015311.md) | [5.2](/filings/0000950170-25-091741.md) | [4.0](/filings/0000950170-24-097132.md) | [2.4](/filings/0000950170-24-127165.md) | [6.1](/filings/0000950170-25-021401.md) | [13.9](/filings/0001193125-26-284027.md) | [2.0](/filings/0000950170-25-109033.md) | [2.3](/filings/0001193125-25-283349.md) | [2.5](/filings/0001193125-26-055008.md) | [3.4](/filings/0001193125-26-349428.md) | [4.3](/filings/0001193125-26-349428.md) |
| Current assets | $m | [34.5](/filings/0000950170-23-063839.md) | [36.2](/filings/0000950170-24-015311.md) | [32.7](/filings/0000950170-25-091741.md) | [31.5](/filings/0000950170-24-097132.md) | [30.2](/filings/0000950170-24-127165.md) | [50.5](/filings/0000950170-25-021401.md) | [38.1](/filings/0001193125-26-284027.md) | [24.9](/filings/0000950170-25-109033.md) | [23.3](/filings/0001193125-25-283349.md) | [29.2](/filings/0001193125-26-055008.md) | [50.8](/filings/0001193125-26-349428.md) | [55.5](/filings/0001193125-26-349428.md) |
| Total assets | $m | [84.7](/filings/0000950170-23-063839.md) | [83.2](/filings/0000950170-24-015311.md) | [64.4](/filings/0000950170-25-091741.md) | [62.3](/filings/0000950170-24-097132.md) | [60.6](/filings/0000950170-24-127165.md) | [80.5](/filings/0000950170-25-021401.md) | [72.5](/filings/0001193125-26-284027.md) | [61.5](/filings/0000950170-25-109033.md) | [61.9](/filings/0001193125-25-283349.md) | [68.6](/filings/0001193125-26-055008.md) | [130](/filings/0001193125-26-349428.md) | [135](/filings/0001193125-26-349428.md) |
| Current liabilities | $m | [35.2](/filings/0000950170-23-063839.md) | [36.7](/filings/0000950170-24-015311.md) | [31.2](/filings/0000950170-25-091741.md) | [32.4](/filings/0000950170-24-097132.md) | [31.4](/filings/0000950170-24-127165.md) | [43.7](/filings/0000950170-25-021401.md) | [34.4](/filings/0001193125-26-284027.md) | [25.1](/filings/0000950170-25-109033.md) | [24.5](/filings/0001193125-25-283349.md) | [30.6](/filings/0001193125-26-055008.md) | [63.0](/filings/0001193125-26-349428.md) | [74.4](/filings/0001193125-26-349428.md) |
| Total liabilities | $m | [38.8](/filings/0000950170-23-063839.md) | [39.9](/filings/0000950170-24-015311.md) | [32.2](/filings/0000950170-25-091741.md) | [32.9](/filings/0000950170-24-097132.md) | [31.8](/filings/0000950170-24-127165.md) | [44.1](/filings/0000950170-25-021401.md) | [34.7](/filings/0001193125-26-284027.md) | [25.4](/filings/0000950170-25-109033.md) | [24.8](/filings/0001193125-25-283349.md) | [30.8](/filings/0001193125-26-055008.md) | [86.9](/filings/0001193125-26-349428.md) | [95.1](/filings/0001193125-26-349428.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [47.1](/filings/0000950170-23-063839.md) | [44.5](/filings/0000950170-24-015311.md) | [33.3](/filings/0000950170-25-091741.md) | [30.5](/filings/0000950170-24-097132.md) | [29.8](/filings/0000950170-24-127165.md) | [37.4](/filings/0000950170-25-021401.md) | [38.8](/filings/0001193125-26-284027.md) | [37.1](/filings/0000950170-25-109033.md) | [38.0](/filings/0001193125-25-283349.md) | [38.6](/filings/0001193125-26-055008.md) | [44.3](/filings/0001193125-26-349428.md) | [40.1](/filings/0001193125-26-349428.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.9) d](/filings/0000950170-24-127165.md) | [(3.1) d](/filings/0000950170-25-021401.md) | [(1.3) d](/filings/0000950170-25-091741.md) | [(2.3)](/filings/0000950170-25-109033.md) | [(0.1) d](/filings/0001193125-25-283349.md) | [7.4 d](/filings/0001193125-26-055008.md) | [12.4 d](/filings/0001193125-26-284027.md) | [(14.3)](/filings/0001193125-26-349428.md) | [(7.4) d](/filings/0001193125-25-283349.md) | [(1.6) d](/filings/0001193125-26-055008.md) | [(3.2) d](/filings/0001193125-26-284027.md) | [(1.0)](/filings/0001193125-26-349428.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-127165.md) | [0.0 d](/filings/0000950170-25-021401.md) | [0.0 d](/filings/0000950170-25-091741.md) | [0.2](/filings/0000950170-25-109033.md) | [0.0 d](/filings/0001193125-25-283349.md) | [0.0 d](/filings/0001193125-26-055008.md) | [0.0 d](/filings/0001193125-26-284027.md) | [0.0](/filings/0000950170-25-109033.md) | [0.0 d](/filings/0001193125-25-283349.md) | [0.0 d](/filings/0001193125-26-055008.md) | [0.0 d](/filings/0001193125-26-284027.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.8](/filings/0000950170-23-063839.md) | [8.9](/filings/0000950170-24-015311.md) | [9.9](/filings/0000950170-24-097132.md) | [12.4](/filings/0000950170-24-127165.md) | [12.8](/filings/0000950170-25-021401.md) | [15.7](/filings/0000950170-25-109033.md) | [15.7](/filings/0001193125-25-283349.md) | [17.8](/filings/0001193125-26-055008.md) | [17.0](/filings/0001193125-26-349428.md) | [18.4](/filings/0001193125-25-283349.md) | [19.2](/filings/0001193125-26-055008.md) | [20.7](/filings/0001193125-26-349428.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,771,387 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349428.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.